Alzheimer’s disease doesn’t arrive suddenly. Instead, it emerges slowly, beginning with subtle changes that might be dismissed as normal aging before progressing through increasingly serious stages of ...

An older oral version of the company's semaglutide drug failed to meet its main goal in late-stage trials testing whether the ...

Novo Nordisk's oral semaglutide drug failed in late-stage Alzheimer's trials, leading to a 10% drop in share price. The ...

Novo Nordisk's closely-watched Alzehimer's trials - which failed on Monday to show it can slow the disease’s progression - ...

Novo Nordisk's older oral semaglutide drug failed in late-stage trials aimed at slowing Alzheimer's cognitive decline, ...

News about Alzheimer's rose to the forefront in 2025, as the FDA approved the first diagnostic blood test and drugmakers ...

Shares in pharmaceutical giant Novo Nordisk slumped on Monday after the company announced that one of its diabetes drugs ...

Novo Nordisk said on Monday an older oral version of its semaglutide drug failed to meet its main ​goal in late-stage trials ...

Novo Nordisk (NVO) announced the top-line results from the 2-year primary analysis of evoke and evoke+ phase 3 trials in early-stage symptomatic ...

The disappointing results mark a significant setback for Novo, which has been exploring Alzheimer’s as a major potential new market for GLP-1 ...